Mark Yarchoan
@markyarchoan.bsky.social
Translational researcher, hepatobiliary oncologist, @JohnsHopkins
Ethan Neumann, a 27-year-old PhD candidate in my lab, devoted himself to studying #fibrolamellar carcinoma, the cancer that claimed his life last week.
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofund.me/f03f47244
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofund.me/f03f47244
Donate to Ethan Neumann Fellowship, organized by Craig Neumann
Ethan Neumann Fellowship
Help establish the Dr. Ethan Neumann Memorial Research Fellowshi… Craig Neumann needs your support for Ethan Neumann Fellowship
www.gofundme.com
December 13, 2025 at 2:47 AM
Ethan Neumann, a 27-year-old PhD candidate in my lab, devoted himself to studying #fibrolamellar carcinoma, the cancer that claimed his life last week.
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofund.me/f03f47244
Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️
gofund.me/f03f47244
New #NEJM report led by Yuxuan Wang
In collaboration with Bert Vogelstein and my lab:
nejm.org/doi/full/10....
➡️ctDNA methylation profiling of blood can identify patients with irAEs
➡️irAEs often involve multiorgan tissue injury
In collaboration with Bert Vogelstein and my lab:
nejm.org/doi/full/10....
➡️ctDNA methylation profiling of blood can identify patients with irAEs
➡️irAEs often involve multiorgan tissue injury
Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events | NEJM
In 6 of 14 patients receiving immune checkpoint inhibitors, cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events, often before symptoms appeared.
nejm.org
December 11, 2025 at 3:16 AM
New #NEJM report led by Yuxuan Wang
In collaboration with Bert Vogelstein and my lab:
nejm.org/doi/full/10....
➡️ctDNA methylation profiling of blood can identify patients with irAEs
➡️irAEs often involve multiorgan tissue injury
In collaboration with Bert Vogelstein and my lab:
nejm.org/doi/full/10....
➡️ctDNA methylation profiling of blood can identify patients with irAEs
➡️irAEs often involve multiorgan tissue injury
We lost someone extraordinary: Ethan Neumann, a PhD candidate in my lab, worked tirelessly to study fibrolamellar carcinoma - the cancer that would ultimately claim his life
Just before his died, he officially earned his doctorate and became Dr. Neumann
→ myarchoan.wixsite.com/yarchoanlabs...
Just before his died, he officially earned his doctorate and became Dr. Neumann
→ myarchoan.wixsite.com/yarchoanlabs...
December 8, 2025 at 2:08 AM
We lost someone extraordinary: Ethan Neumann, a PhD candidate in my lab, worked tirelessly to study fibrolamellar carcinoma - the cancer that would ultimately claim his life
Just before his died, he officially earned his doctorate and became Dr. Neumann
→ myarchoan.wixsite.com/yarchoanlabs...
Just before his died, he officially earned his doctorate and became Dr. Neumann
→ myarchoan.wixsite.com/yarchoanlabs...
Reposted by Mark Yarchoan
Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @markyarchoan.bsky.social & @pogorely.bsky.social www.nature.com/articles/s41...
TIRTL-seq: deep, quantitative and affordable paired TCR repertoire sequencing - Nature Methods
TIRTL-seq is a high-throughput method for paired T cell receptor sequencing at the cohort scale.
www.nature.com
November 24, 2025 at 9:38 PM
Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @markyarchoan.bsky.social & @pogorely.bsky.social www.nature.com/articles/s41...
Reposted by Mark Yarchoan
1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...
Serum Procalcitonin: A Novel Tumor Biomarker for Diagnosis and Follow-Up in Fibrolamellar Hepatocellular Carcinoma
Introduction: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers (alpha-fetoprotein (AFP) and CA19-9). An o...
www.medrxiv.org
November 23, 2025 at 10:59 AM
1) We recently identified as serum tumor biomarker of fibrolamellar carcinoma, procalcitonin, with @zucmanrossi.bsky.social and @markyarchoan.bsky.social that you can find in www.medrxiv.org/content/10.1...
1/ Our new review is out today in Nature Reviews Cancer—on why therapeutic cancer vaccines are finally gaining traction after decades of setbacks.
🔗 rdcu.be/emkkd
w/
@NeehaZaidi
@DrLizJaffee
Key takeaways below
🔗 rdcu.be/emkkd
w/
@NeehaZaidi
@DrLizJaffee
Key takeaways below
Recent advances in therapeutic cancer vaccines
Nature Reviews Cancer - Cancer prevention vaccines have reduced cancer-related mortalities, yet therapeutic cancer vaccine development and clinical translation continues to face challenges. Here,...
rdcu.be
May 16, 2025 at 1:50 PM
1/ Our new review is out today in Nature Reviews Cancer—on why therapeutic cancer vaccines are finally gaining traction after decades of setbacks.
🔗 rdcu.be/emkkd
w/
@NeehaZaidi
@DrLizJaffee
Key takeaways below
🔗 rdcu.be/emkkd
w/
@NeehaZaidi
@DrLizJaffee
Key takeaways below
New study led by @danielzabransky.bsky.social lab
Older adults respond well to anti-PD1 therapy, despite age-related immune changes
🔗 nature.com/articles/s41...
Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells
Older adults respond well to anti-PD1 therapy, despite age-related immune changes
🔗 nature.com/articles/s41...
Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells
Age-related divergence of circulating immune responses in patients with solid tumors treated with immune checkpoint inhibitors - Nature Communications
The aging immune system is characterized by changes in immune cell frequencies and functionality. Here the authors report dynamics of age-related divergence of circulating immune responses in patients...
nature.com
April 21, 2025 at 3:02 PM
New study led by @danielzabransky.bsky.social lab
Older adults respond well to anti-PD1 therapy, despite age-related immune changes
🔗 nature.com/articles/s41...
Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells
Older adults respond well to anti-PD1 therapy, despite age-related immune changes
🔗 nature.com/articles/s41...
Findings unlikely to extend to other forms of immunotherapy (eg cancer vaccines, etc.) which rely on naive T cells
Reposted by Mark Yarchoan
Nakazawa et al. studied the peripheral immune profile of a cohort of patients with advanced solid tumors; 54 patients received anti-PD-(L)1 alone and 50 received anti-PD-(L)1 + anti-CTLA-4. bit.ly/42qWx4d @markyarchoan.bsky.social
April 18, 2025 at 3:30 PM
Nakazawa et al. studied the peripheral immune profile of a cohort of patients with advanced solid tumors; 54 patients received anti-PD-(L)1 alone and 50 received anti-PD-(L)1 + anti-CTLA-4. bit.ly/42qWx4d @markyarchoan.bsky.social
Reposted by Mark Yarchoan
Anti-vascular endothelial growth factor enhances immune checkpoint inhibition by reprogramming regulatory T cells into a fragile state @cp-immunity.bsky.social @markyarchoan.bsky.social
www.cell.com/immunity/ful...
on
www.cell.com/immunity/ful...
www.cell.com/immunity/ful...
on
www.cell.com/immunity/ful...
April 10, 2025 at 5:19 PM
Anti-vascular endothelial growth factor enhances immune checkpoint inhibition by reprogramming regulatory T cells into a fragile state @cp-immunity.bsky.social @markyarchoan.bsky.social
www.cell.com/immunity/ful...
on
www.cell.com/immunity/ful...
www.cell.com/immunity/ful...
on
www.cell.com/immunity/ful...
1/
Exciting work published in Immunity from @TimGreten et al. showing that anti-VEGF enhances the antitumor activity of PD-L1 + CTLA-4 blockade by inducing a fragile Treg phenotype via BAFF and IL-12
📄 www.cell.com/immunity/ful...
Exciting work published in Immunity from @TimGreten et al. showing that anti-VEGF enhances the antitumor activity of PD-L1 + CTLA-4 blockade by inducing a fragile Treg phenotype via BAFF and IL-12
📄 www.cell.com/immunity/ful...
Anti-vascular endothelial growth factor treatment potentiates immune checkpoint blockade through a BAFF- and IL-12-dependent reprogramming of the TME
VEGF blockade is known to enhance immune checkpoint blockade (ICB) efficacy, but its
precise immunological mechanism remains undefined. Benmebarek et al. reveal that VEGF
inhibition drives BAFF- and I...
www.cell.com
April 10, 2025 at 9:56 PM
1/
Exciting work published in Immunity from @TimGreten et al. showing that anti-VEGF enhances the antitumor activity of PD-L1 + CTLA-4 blockade by inducing a fragile Treg phenotype via BAFF and IL-12
📄 www.cell.com/immunity/ful...
Exciting work published in Immunity from @TimGreten et al. showing that anti-VEGF enhances the antitumor activity of PD-L1 + CTLA-4 blockade by inducing a fragile Treg phenotype via BAFF and IL-12
📄 www.cell.com/immunity/ful...
🚨 New manuscript led by Marina Baretti
Using #CODEX multiplexed imaging:
🧬 #CCA is rich in CAFs,TAMs,MDSCs, scarce CD8 T cells (~1.8% of all cells)
🧬 FGFR2 fusions → ⬆️ CD11b+/CD15+ granulocytes
🧬 IDH1 mutations → trend ⬆️M2-like mac
▶️ pubmed.ncbi.nlm.nih.gov/39969434/
Using #CODEX multiplexed imaging:
🧬 #CCA is rich in CAFs,TAMs,MDSCs, scarce CD8 T cells (~1.8% of all cells)
🧬 FGFR2 fusions → ⬆️ CD11b+/CD15+ granulocytes
🧬 IDH1 mutations → trend ⬆️M2-like mac
▶️ pubmed.ncbi.nlm.nih.gov/39969434/
February 24, 2025 at 6:05 PM
🚨 New manuscript led by Marina Baretti
Using #CODEX multiplexed imaging:
🧬 #CCA is rich in CAFs,TAMs,MDSCs, scarce CD8 T cells (~1.8% of all cells)
🧬 FGFR2 fusions → ⬆️ CD11b+/CD15+ granulocytes
🧬 IDH1 mutations → trend ⬆️M2-like mac
▶️ pubmed.ncbi.nlm.nih.gov/39969434/
Using #CODEX multiplexed imaging:
🧬 #CCA is rich in CAFs,TAMs,MDSCs, scarce CD8 T cells (~1.8% of all cells)
🧬 FGFR2 fusions → ⬆️ CD11b+/CD15+ granulocytes
🧬 IDH1 mutations → trend ⬆️M2-like mac
▶️ pubmed.ncbi.nlm.nih.gov/39969434/
Our first 2025 paper was published today in JITC
Explores the "obesity paradox" in cancer immunotherapy:
1️⃣ Obese patients have better IO outcomes (despite ⬆️cancer risk)
2️⃣ Obesity → ⬆️T-cell exhaustion →⬆️ ICI benefit
doi.org/10.1136/jitc...
January 22, 2025 at 2:36 AM
Our first 2025 paper was published today in JITC
Explores the "obesity paradox" in cancer immunotherapy:
1️⃣ Obese patients have better IO outcomes (despite ⬆️cancer risk)
2️⃣ Obesity → ⬆️T-cell exhaustion →⬆️ ICI benefit
doi.org/10.1136/jitc...
Excited to share our latest study in Nature Immunology on TLS in #HCC patients treated w/ neoadj ICB:
⏩ TLS linked to improved outcomes
⏩ Novel "involuted" TLS found in tumor regression zones
🔗 nature.com/articles/s41...
⏩ TLS linked to improved outcomes
⏩ Novel "involuted" TLS found in tumor regression zones
🔗 nature.com/articles/s41...
November 15, 2024 at 4:51 AM
Excited to share our latest study in Nature Immunology on TLS in #HCC patients treated w/ neoadj ICB:
⏩ TLS linked to improved outcomes
⏩ Novel "involuted" TLS found in tumor regression zones
🔗 nature.com/articles/s41...
⏩ TLS linked to improved outcomes
⏩ Novel "involuted" TLS found in tumor regression zones
🔗 nature.com/articles/s41...